Full product name
Von Hippel-Lindau disease tumor suppressor
Code
BT-AP15470
Host
Rabbit
Isotype
IgG
Size
100ul,50ul,20ul
Clonality
Polyclonal
Immunogen
The antiserum was produced against synthesized peptide derived from human VHL around the phosphorylation site of Ser68. AA range:34-83
Purification
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration
1 mg/ml
Formulation
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Storage
-20°C for 1 year
Background
Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.
Uniprot accession
Molecular weight
24153
Gene ID
Human: 7428; Mouse: 22346; Rat: 24874
Synonyms
Von Hippel-Lindau disease tumor suppressor; VHL; Von Hippel-Lindau disease tumor suppressor; Protein G7; pVHL
Research area
Metabolism; Cancer; Cell biology; Epigenetics and nuclear signaling
Target protein
VHL
